Antibacterial combination therapy

A composition, phenyl technology, applied in the direction of antibacterial drugs, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as limited treatment options

Inactive Publication Date: 2011-01-05
E THERAPEUTICS LTD
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Currently, treatment options for infections caused by or caused by VISA or VRSA are very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial combination therapy
  • Antibacterial combination therapy
  • Antibacterial combination therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0075] method:

[0076] In exemplary experiments, miconazole nitrate, econazole nitrate, clotrimazole and disulfiram or DDS were dissolved in DMSO. The experiment was repeated using disulfiram or DDS dissolved in ethanol. Other solvents that can be used include castor oil, pyridine, and 0.9% saline. Agents for intravenous administration can be dissolved in polyethoxylated castor oil, or cyclodextrins (e.g., sulfobutyl ether 7 -β-cyclodextrin or hydroxypropyl-β-cyclodextrin) and lactic acid. Following BSAC (British Society for Antimicrobial Chemotherapy) guidelines (Andrews 2001), the minimum inhibitory concentrations (MIC) of individual agents and combinations of agents, briefly described below, were determined against a range of clinical pathogens and controls. MICs were determined by agar dilution (test A) and broth microdilution (test B).

[0077] Preparation of agar plates and broth

[0078] Stock solutions of each agent were prepared using the following formula.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.

Description

technical field [0001] The present invention provides a product comprising a synergistic combination of disulfiram or its derivatives or its metabolites and a therapeutically active imidazole as a combined preparation for treating infections caused or caused by multi-drug resistant bacteria. Background technique [0002] Microorganisms develop or acquire pathways to overcome the inhibitory effects of antibiotics as a result of the heavy use of these drugs in human medicine and animal husbandry, indiscriminate prescribing, and patient non-compliance with treatment regimens. Therapeutic options for treating these resistant microorganisms, especially bacteria, are increasingly limited. The proliferation of resistant microorganisms and the spread of resistance genes among bacteria exacerbates the problem of antibiotic resistance. The threat posed by the emergence and spread of antibiotic resistance to the successful treatment of bacterial infections is one of the most important...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4174A61K31/145A61P31/04
CPCA61K31/145A61K45/06A61K31/4174A61P31/04A61K2300/00
Inventor 马尔科姆·菲利普·扬凯瑟琳·玛莉·托马斯奥卢索拉·克莱门特·伊多武朱莉·安妮·查尔顿
Owner E THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap